bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
Company profile
Ticker
BIAF, BIAFW
Exchange
Website
CEO
Ms. Maria Zannes J.D.
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
OncoSelect® Therapeutics, LLC • Precision Pathology Laboratory Services, LLC ...
IRS number
465211056
BIAF stock data
Latest filings (excl ownership)
424B3
Prospectus supplement
23 Sep 24
EFFECT
Notice of effectiveness
20 Sep 24
S-1
IPO registration
11 Sep 24
DEF 14A
Definitive proxy
5 Sep 24
PRE 14A
Preliminary proxy
23 Aug 24
8-K
Departure of Directors or Certain Officers
23 Aug 24
424B3
Prospectus supplement
14 Aug 24
424B3
Prospectus supplement
14 Aug 24
10-Q
2024 Q2
Quarterly report
14 Aug 24
D
$1.30 mm in equity / options / securities to be acquired, sold $1.30 mm, 3 investors
12 Aug 24
Transcripts
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 801.31 k | 801.31 k | 801.31 k | 801.31 k | 801.31 k | 801.31 k |
Cash burn (monthly) | 550.62 k | 623.16 k | 701.62 k | 727.36 k | 510.81 k | 585.60 k |
Cash used (since last report) | 1.56 mm | 1.76 mm | 1.99 mm | 2.06 mm | 1.45 mm | 1.66 mm |
Cash remaining | -758.04 k | -963.47 k | -1.19 mm | -1.26 mm | -645.30 k | -857.12 k |
Runway (months of cash) | -1.4 | -1.5 | -1.7 | -1.7 | -1.3 | -1.5 |
Institutional ownership, Q2 2024
7.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 17 |
Opened positions | 5 |
Closed positions | 2 |
Increased positions | 6 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 863.92 mm |
Total shares | 1.00 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Roby Joyce | 603.13 k | $1.01 mm |
Vanguard | 171.99 k | $371.51 mm |
Geode Capital Management | 69.60 k | $150.34 mm |
Captrust Financial Advisors | 27.89 k | $60.23 mm |
Renaissance Technologies | 22.97 k | $49.61 mm |
Ground Swell Capital | 22.86 k | $49.39 mm |
STT State Street | 17.60 k | $38.02 mm |
Sheaff Brock Investment Advisors | 15.00 k | $32.40 mm |
NTRS Northern Trust | 13.66 k | $29.51 mm |
Creative Planning | 12.60 k | $27.21 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Jul 24 | Stuart Diamond | Common Stock | Grant | Acquire A | No | No | 0 | 33,784 | 0.00 | 99,088 |
1 Jul 24 | Steven Girgenti | Common Stock | Grant | Acquire A | No | No | 0 | 33,784 | 0.00 | 1,065,248 |
1 Jul 24 | Robert A. Anderson | Common Stock | Grant | Acquire A | No | No | 0 | 33,784 | 0.00 | 163,936 |
1 Jul 24 | Roby Joyce | Common Stock | Grant | Acquire A | No | No | 0 | 33,784 | 0.00 | 66,615 |
News
bioAffinity Technologies' CyPath Lung Test Shows Potential Significant Healthcare Savings By Reducing Unnecessary Follow-Up, Medical Complications And Overdiagnosis In Peer-Reviewed Study
18 Sep 24
bioAffinity Technologies Q2 EPS $(0.19) Up From $(0.20) YoY, Sales $2.40M Up From $19.74K YoY
14 Aug 24
Crude Oil Falls Sharply; Exxon Mobil Earnings Top Views
2 Aug 24
Nasdaq Tumbles 3%; US Economy Adds 114,000 Jobs In July
2 Aug 24
Dow Dips Over 400 Points; Apple Posts Upbeat Earnings
2 Aug 24
Press releases
Peer-Reviewed Study: bioAffinity Technologies' CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis
18 Sep 24
bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO
23 Aug 24
bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales
14 Aug 24
WallachBeth Capital Announces Closing of bioAffinity Technologies Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
5 Aug 24
bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
5 Aug 24